Podcast Episodes
Back to Search
Ep. 80 - Vertex’s Winning Formula: Altshuler on Choosing the Next Breakthroughs
Season 4 Episode 80
Vertex’s approach to research, defined over a decade ago to beat the dismal odds of success in biotech, remains core to its strategy, even as the ind…
1 year, 5 months ago
Ep. 79 - BNP Paribas’ Moneer on Biotech’s Bull Case: M&A, PE, and Market Recovery
Season 4 Episode 79
Since the annual J.P. Morgan Healthcare Conference in San Francisco in early January, biotech has seen a notable surge in enthusiasm, Zahid Moneer, s…
1 year, 5 months ago
Ep. 78 - Biotech’s New Normal: SR One’s Simeon George on Adapting to Market Constraints
Season 4 Episode 78
Biotechs need to get used to the new normal, says SR One CEO and Managing Partner Simeon George, and that will require significant adjustments to the…
1 year, 6 months ago
Ep. 77 - AI’s Next Leap: Foresite Labs’ Vik Bajaj on Predictive Biology
Season 4 Episode 77
Clinical trials will be launched in the next year or two to test predictions about causal biology made by artificial intelligence models, Vik Bajaj, …
1 year, 6 months ago
Ep. 76 - FDA Inflection Point: Steve Usdin on Biopharma during Trump 2.0
Season 4 Episode 76
All presidential transitions with a change of party come with disruption and threats as well as opportunities. But this one, in particular with regar…
1 year, 7 months ago
Ep. 75 - PBMs, IRA, RFK Jr: A Conversation With Rep. Jake Auchincloss
Season 4 Episode 75
Rep. Jake Auchincloss (D-Mass.), an influential voice in Congress on life sciences issues, gained stature last week when he was appointed to serve on…
1 year, 7 months ago
Ep. 74 - Chris Bardon on Biotech’s Recovery: Valuations, Obesity Drugs, and M&A
Season 4 Episode 74
Specialist public investors are doing their best to hold up the sector, but biotech still has to wash out many of the lower quality companies that we…
1 year, 7 months ago
Ep. 73 - Resilience and the CEO’s Paradox: Aoife Brennan on Leading in Biotech
Season 3 Episode 73
Leading biotech companies through the turbulence of the past few years and the uncertainty of the next ones takes not just resilience, but an ability…
1 year, 8 months ago
Ep. 72 - Outlook for Biotech M&A and Financing: Sidley's Robert Darwin
Season 3 Episode 72
With new governments both side of the pond, capital markets picking up, and some geopolitical overhang, there’s a mixed feast for biotech, with a net…
1 year, 9 months ago
Ep. 71 - Pazdur Unplugged: FDA Director Richard Pazdur on the Past, Future of Cancer Treatments
Season 3 Episode 71
Richard Pazdur, director of FDA’s Oncology Center of Excellence, joined FDA in 1999. Looking back on his 25th anniversary, he draws a line between un…
1 year, 10 months ago